Resources Guide

Therapy Initiation Resources

  • QOPI Measures
    • QOPI Core13oral4 – Documented plan for oral chemotherapy (defect-free measure, Core13oral4a-Core13oral4d)
    • QOPI Core13oral4a – Documented plan for oral chemotherapy: dose
    • QOPI Core13oral4b – Documented plan for oral chemotherapy: provided to patient/caregiver prior to start of therapy and practitioner(s) providing continuing care (PCP) within 3 months of starting therapy
    • QOPI Core13oral4c – Documented plan for oral chemotherapy: indications

Education Resources

  • QOPI Measures
    • QOPI Core13oral5 – Oral chemotherapy education provided prior to the start of therapy (defect-free measure, Core13oral5a-Core13oral5c)
    • QOPI Core13oral5a – Oral chemotherapy education provided prior to the start of therapy: missed doses
    • QOPI Core13oral5b – Oral chemotherapy education provided prior to the start of therapy: toxicities
    • QOPI Core13oral5a – Oral chemotherapy education provided prior to the start of therapy: clinic contact instructions

Drug Specific Resources

Drug NamePatient
Self-Management Education
PCP
Information
Video Education
for Staff
(Coming Soon)
Prior Authorization Information
(Coming Soon)
Abiraterone (Zytiga)

Afatinib (Gilotrif)
Alectinib (Alecensa)
Axitinib (Inlyta)

Bexarotene (Targretin)http://moqc.org/wp-content/uploads/2017/07/Bexarotene.doc
Bosutinib (Bosulif)
Cabozantinib (Cabometyx)
Capecitabine (Xeloda)
Ceritinib (Zykadia)
Chlorambucil (Leukeran)
Cobimetinib (Cotellic)
Crizotinib (Xalkori)
Cyclophosphamide (Cytoxan)
Dabrafenib (Tafinlar)
Dasatinib (Sprycel)
Enzalutamide (Xtandi)
Erlotinib (Tarceva)
Etoposide (Etopophos, Toposar)
Everolimus (Afinitor)
Gefitinib (Iressa)
Hydroxyurea (Hydrea, Droxia)
Ibrutinib (Imbruvica)
Idelalisib (Zydelig)
Imatinib (Gleevec)
Ixazomib (Ninlaro)
Lapatinib (Tykerb)
Lenalidomide (Revlimid)
Lenvatinib (Lenvima)
Lomustine (CCNU, Ceenu)
Melphalan (Alkeran)
Mercaptopurine (Purinethol, Purixan)
Methotrexate (Trexall, Rasuvo)
Nilotinib (Tasigna)
Olaparib (Lynparza)
Osimertinib (Tagrisso, Tagrix)
Palbociclib (Ibrance)
Panobinostat (Farydak)
Pazopanib (Votrient)
Pomalidomide (Pomalyst)
Ponatinib (Iclusig)
Procarbazine (Matulane)
Regorafenib (Stivarga)
Rucaparib (Rubraca)
Ruxolitinib (Jakafi)
Sonidegib (odomzo)
Sorafenib (Nexavar)
Sunitinib (Sutent)
Temozolomide (Temodar)
Thalidomide (Thalomid)
Thioguanine (Tabloid)
Topotecan (Hycamtin)
Trametinib (Mekinist)
Tretinoin (Refissa, Atralin, Tretin-X, Retin-A, Avita, and Renova)
Vandetanib (Caprelsa)
Vemurafenib (Zelboraf)
Venetoclax (Venclexta)
Vismodegib (Erivedge)
Vorinostat (Zolinga)

Monitoring Resources

  • QOPI Measures

    • QOPI Core13oral6 – Oral chemotherapy monitored on visit/contact following start of therapy (defect-free measure, Core13oral6a-Core13oral6b)
    • QOPI Core13oral6a – Oral chemotherapy monitored on visit/contact following start of therapy: medication adherence assessed
    • QOPI Core13oral6b – Oral chemotherapy monitored on visit/contact following start of therapy: medication adherence addressed